<DOC>
	<DOCNO>NCT00857662</DOCNO>
	<brief_summary>Test whether AVMs treat Onyx equivalent treatment n-BCA . Success define AVM size reduction great 50 %</brief_summary>
	<brief_title>Study Comparing Onyx TRUFILL Brain Arteriovenous Malformations ( AVMs )</brief_title>
	<detailed_description>Recent advance endovascular treatment arteriovenous malformation ( AVMs ) increase number patient brain AVMs embolization therapy may appropriate . The permanency obliterate nidi occurrence procedural complication think least partially influenced characteristic material use , liquid agent likely reach occlude AVM nidus compare particulate embolic agent . The liquid embolic agent approve U.S. presurgical embolization AVMs TRUFILL® . TRUFILL n-butyl cyanoacrylate ( n-BCA ) liquid adhesive polymerizes solid material upon contact blood fluid tissue , via anionic mechanism . TRUFILL Ethiodized Oil mixed n-BCA monomer radiopaque polymerize retardant . TRUFILL Tantalum Powder may also add radiopacity . The TRUFILL n-BCA Liquid Embolic System receive U.S. FDA premarket approval September 25 , 2000 ( P990040 ) use embolization cerebral AVMs , presurgical devascularization desire . Onyx™ non-adhesive liquid embolic agent comprise ethylene vinyl alcohol ( EVOH ) copolymer dissolve dimethyl sulfoxide ( DMSO ) , micronized tantalum powder . Onyx precipitate solid contact blood fluid , due rapid diffusion DMSO solvent . The Onyx Liquid Embolic System receive European `` CE mark '' July 1999 , available outside U.S. since September 1999 use embolization AVMs . The purpose randomized-controlled study obtain prospective clinical data performance Onyx ( investigational device ) TRUFILL ( control device ) presurgical embolization brain AVMs . Device safety assess compare overall device-related morbidity mortality . The primary efficacy endpoint angiographic reduction AVM size ( volume ) achieve . The objective demonstrate Onyx bad TRUFILL within specify clinical tolerance . Study result use support premarket approval application Onyx presurgical embolization brain AVMs .</detailed_description>
	<mesh_term>Congenital Abnormalities</mesh_term>
	<mesh_term>Arteriovenous Malformations</mesh_term>
	<mesh_term>Hemangioma</mesh_term>
	<criteria>The patient patient 's guardian understands sign inform consent procedure The patient confirm diagnosis brain AVM cerebral cortex , cerebellum dura mater visualize angiography cross sectional imaging . The brain AVM SpetzlerMartin grade I , II , III , IV . If brain AVM SpetzlerMartin grade I II , anticipated benefit embolization surgical resection great risk embolization procedure ( e.g. , patient stability ) . The patient candidate surgical resection AVM post embolization . The patient clinically neurologically stable , minimum 24 hour prior embolization . The patient agree , capable completing , studyrelated exams procedure . Patient age . The patient pregnant . The patient brain AVM high flow arteriovenous fistulae investigator determine unsuitable embolization . The brain AVM SpetzlerMartin grade V. The patient participate another research study involve another investigational device , procedure drug . The brain AVM previously treat another embolization agent</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>US Multicenter</keyword>
	<keyword>Randomized</keyword>
	<keyword>Onyx</keyword>
	<keyword>Brain Arteriovenous Malformation ( BAVMs )</keyword>
</DOC>